Short Courses

Phenotypic Screening: Why, When and How

Sunday, February 4
8:00 AM - 3:15 PM
Location: 10

Phenotypic screening is experiencing a Renaissance in the pharmaceutical industry, based on its successful track record in delivering first-in-class medicines stemming from novel biology. Although phenotypic screening may appear at first sight to be similar to target-based screening, there are some fundamental differences between the two approaches.  
This course will deliver a theoretical and practical framework for the use of phenotypic drug discovery by (1) providing a broad context of the drug discovery process, (2) comparing and contrasting molecular target driven and empirical phenotypic drug discovery strategies, (3) providing guidelines on why and when to utilize an empirical phenotypic drug discovery approach and (4) providing practical information to prosecute phenotypic programs more effectively. 

Additional fees apply. Visit http://www.slas2018.org/program/short-course-program/ for more information.

ViewAttendees 3

Fabien Vincent

Associate Research Fellow
Pfizer

Fabien Vincent, Ph.D., is Associate Research Fellow in the department of Hit Discovery and Lead Profiling at Pfizer. He received a Diplome d’Ingenieur in organic chemistry from CPE Lyon (France) before conducting graduate research in the fields of chemical biology and enzymology in the laboratory of Pr. Harold Kohn at the University of Houston. He later became a post-doctoral fellow in chemical biology at the Genomics Institute of the Novartis Research Foundation in San Diego. Fabien Vincent then entered the field of drug discovery as both a research project leader and molecular pharmacology group leader. His main research interests are centered on improving the translation of pre-clinical research to patients and specifically include physiologically relevant assays, phenotypic screening and atypical molecular mechanisms of action.

Presentation(s):

ViewAttendees 3

Send Email for Fabien Vincent

Jonathan Lee

Senior Research Advisor
Eli Lilly

Presentation(s):

ViewAttendees 3

Send Email for Jonathan Lee

David C. Swinney

CEO
Institute for Rare and Neglected Diseases Drug Discovery

David Swinney has over 25 years of industrial drug discovery experience (Roche, Syntex, iRND3) working to identify promising leads, clinical candidates and effective mechanisms of drug action that address unmet medical needs. He has a PhD in medicinal chemistry from the University of Washington, Seattle, and expertise in drug discovery, drug discovery strategies, assay development and screening, enzymology, pharmacology and binding kinetics. Dave is currently at the non-profit Institute for Rare and Neglected Diseases Drug Discovery in Mountain View, CA, aka iRND3, (www.irnd3.org) working to help discover new medicines for rare and neglected diseases.

Presentation(s):

ViewAttendees 3

Send Email for David Swinney


Assets

Phenotypic Screening: Why, When and How



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Phenotypic Screening: Why, When and How